Cybin Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
HELP Nasdaq 2834 cybin.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cybin Inc.

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director - May 13th, 2026 6:00 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - May 4th, 2026 9:11 am
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - Apr 30th, 2026 5:17 pm
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference - Apr 30th, 2026 5:30 am
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - Apr 28th, 2026 5:30 am
Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk? - Apr 25th, 2026 6:05 am
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain - Apr 24th, 2026 8:19 am
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan - Apr 23rd, 2026 5:30 am
Trump Signed a Psychedelic Drugs Order—and These 4 Stocks Surged - Apr 20th, 2026 2:34 pm
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions - Apr 20th, 2026 6:15 am
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer - Apr 20th, 2026 6:00 am
Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness - Apr 20th, 2026 5:23 am
Cybin Insider Ups Holding By 105% During Year - Apr 19th, 2026 6:17 am
Trump Trade: President to sign order on psychedelic used for PTSD - Apr 17th, 2026 3:56 pm
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs - Apr 16th, 2026 5:30 am
Will Psychedelic Stocks Have A Trippy Ride Under RFK Jr.? - Apr 2nd, 2026 9:31 am
Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study Data - Mar 24th, 2026 11:34 pm
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer - Mar 12th, 2026 5:30 am
A Look At Cybin (HELP) Valuation After Positive Phase 2 HLP004 Anxiety Data - Mar 8th, 2026 11:05 pm
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results - Mar 6th, 2026 8:15 am